Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

958 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients. Drug-eluting stents are specifically designed to prevent the problem of in-stent restenosis. They consist of a selective anti-proliferative drug, sirolimus, a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, sirolimus elutes into the vessel wall and stops the process of neointimal hyperplasia, thereby significantly reducing the incidence of in-stent restenosis.

The study "Prevention of Coronary Restenosis" examines the effectiveness of sirolimus-eluting stents (SES) compared to bare-metal stents (BMS) in patients with coronary stenosis. The goal of the study is to examine whether the guideline-supported implantation of SES, despite the higher initial cost, improves the quality and economic outcomes of the treatment of patients with coronary stenosis. Secondarily, the study evaluates patient quality of life, impairment of daily activities, re-intervention rate, as well as an account of the utilisation and benefits of the implemented standardised guidelines.

In this prospective, multi-centre, country-wide cohort study, 658 patients undergoing an implantation of a SES for treatment of coronary stenosis were recruited from 35 hospital centres. Their treatment and outcomes will be evaluated over a 3-year period by means of standardised questionnaires. In addition, information obtained from the patients will be confirmed and augmented by telephone interviews with the attending physicians involved in their follow-up care.

In order to appraise the effect of the new therapy, a comparison cohort group of 394 patients receiving a BMS was recruited. These patients will be evaluated and observed by the same method as those patients receiving a drug-eluting stent, also over 3 years

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Economic Evaluation German Drug-Eluting Stent Registry

NCT00866398

Coronary Heart Disease

COMPLETED

Sirolimus-Eluting Stents for Chronic Total Coronary Occlusions

NCT00258596

Coronary Artery Disease Coronary Disease Coronary Stenosis

COMPLETED PHASE3

Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions

NCT01516723

Coronary Artery Disease Coronary Disease Coronary Stenosis

UNKNOWN PHASE3

Sirolimus-eluting Stents With Biodegradable Polymer Versus an Everolimus-eluting Stents

NCT01443104

Coronary Artery Disease Angina Pectoris Myocardial Infarction

COMPLETED NA

Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions

NCT00611910

Arteriosclerosis of Arterial Coronary Artery Bypass Graft

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BMS

Implantation of a bare metal stent

Group Type OTHER

bare metal stent

Intervention Type DEVICE

implantation of a bare metal stent

SES

Implantation of a sirolimus-eluting stent

Group Type OTHER

Cypher-Stent (Implantation of a sirolimus-eluting stent)

Intervention Type DEVICE

Implantation of a sirolimus-eluting stent

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bare metal stent

implantation of a bare metal stent

Intervention Type DEVICE

Cypher-Stent (Implantation of a sirolimus-eluting stent)

Implantation of a sirolimus-eluting stent

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cypher-Stent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* indication for implantation of a coronary stent
* de novo lesions \< or = 30 mm in patients with diabetes
* de novo lesions 12-30 mm or RVD 2.5-3.00 mm in patients without diabetes

Exclusion Criteria

* acute MI
* lesion length \>30 mm
* in-stent restenosis
* distal lesion in RVD \< 2.25 mm
* lesion in left main or bypass vessel
* contraindication to Clopidogrel

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes